Medicure Inc.

Related Content

Aggrastat Bolus Vial, IV antiplatelet agent
Technology | Antiplatelet and Anticoagulation Therapies
FDA Approves Aggrastat Bolus Vial to Improve Delivery in the Cath Lab

October 28, 2016 — Medicure Inc. recently received U.S. Food and Drug Administration (FDA) market clearance for its new ...

Home October 28, 2016
arrow
News
Medicure Completes Enrollment in CABG II Trial

September 20, 2007 - Medicure Inc. today announced the completion of enrollment of 3,000 patients in its MEND-CABG II ...

Home September 19, 2007
arrow
News
FDA Puts Medicure’s Ischemia Drug on the Fast Track

May 18, 2007 — Medicure, a biopharmaceutical company focused on the research, development and commercialization of novel ...

Home May 17, 2007
arrow
News
Protective Effects of MC-1 Shown in CABG Patients

Results from the Phase II MEND-CABG study — which looked at demonstrated the clinical benefits of MC-1 in reducing ...

Home November 05, 2006
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now